Blog

An Industry Insider’s Look at Global Pharma 2016

CPhI Worldwide has come and gone and beautiful Barcelona is but a memory. However, pharmaceutical industry insiders have come away with interesting perspectives on the road ahead. A recent piece by William Looney of Pharmaceutical Executive caught our…


China Rising: Trans-Pacific Health Sciences Dialogue

A survey conducted by Biopharma Reporter today reported that North America and Western Europe are considered the most important pharmaceutical markets today, coming in at 88 percent and 71 percent respectively. China slipped in at third place thanks…


The Biosimilar Tsunami and Pharmaceutical Balance Sheets – The Lesson of Sisyphus

Within a fortnight, the operational environment for many global pharmaceutical companies will be indelibly changed forever. On July 12-13, 2016, two anti-TNF (tumor necrosis factor) biosimilars went before an independent scientific advisory committee to the U.S. FDA seeking…


2016 G20 Summit: Will China Prevail?

Today BBC China editor Carrie Gracie published a thoughtful article on the G20 Summit set to begin September 4 in Hangzhou, China. The city, usually enveloped in manufacturing haze, is swathed in a brilliant blue sky, a reflection…


PaizaBio’s Deere to Reveal Global Pharma’s Salvation at CPhI Pharma Insights

“China is in the midst of regulatory ‘shock and awe.’ PaizaBio provides multinational pharmaceutical companies with much needed on-the-ground insight and a clear path forward in China.” October 4, 2016 I 2:30 PM I Pharma Forum Theater 1,…


Regulatory Reform in China Creates Opportunities

Pharmaceutical Technology features David Deere’s insight article that reports that quality, innovation, and new approval pathways open drug development options for the Chinese market, including injectable contract manufacturing. Read More


CFDA Drug Regulatory Reforms and The Art of War

  “Let your plans be dark and impenetrable as night and when you move, fall like a thunderbolt.” Sun Tzu, The Art of War Sun Tzu’s The Art of War is a time-honored classic that defines the strategies…


Pfizer Confirms Big Pharma Is Beginning the March to China

The focus of Pfizer’s recent second quarter earnings call came as no surprise to PaizaBio, but was likely to have raised a few eyebrows from the investment community and among global pharmaceutical executives. Not only did CEO Ian…


Bill Gates, the CFDA and the Trans-Pacific Aseptic Institute of Training™

Former Microsoft CEO Bill Gates and his wife Melinda are arguably two of the most visible philanthropists in the world, operating under the mantra that “we are impatient optimists working to reduce inequity.” In June, the Bill &…


As the Patent Cliff Promises to Obliterate Profits, China Beckons

Tuesday’s decision by a federal judge to deny AstraZeneca’s attempt to extend patent protection on its multi-billion dollar Crestor franchise sent a reminder to the global pharmaceutical industry, which has quietly attempted to ignore an impending reality: The…